■生物制剂彻底改变了肿瘤学等专业的护理,免疫学,传染病,和遗传性疾病,对特定分子或选择免疫细胞提供靶向作用。单克隆抗体,以其高特异性和精确性而闻名,代表了这些代理中最重要和最迅速扩展的类别之一。了解单克隆抗体的药物利用模式对于确保其最佳使用至关重要。特别是考虑到它们的高成本和潜在的不利影响。
■这项分析性横断面研究是在阿拉伯联合酋长国的一家二级医院进行的。包括在研究部位接受单克隆抗体的两种性别的患者。治疗模式,利用率,并评估了与单克隆抗体停用相关的因素.
■高脂血症(136,39.1%)是单克隆抗体最常见的适应症,其次是预防先天性心脏病(104,29.9%)和骨质疏松症(42,12.1%)的呼吸道合胞病毒感染。Evolocumab是最常用的单克隆抗体(135,38.8%),其次是帕利珠单抗(104,29.9%),和dupilumab(38,10.9%)。大多数单克隆抗体显示出处方日剂量与确定日剂量的比率为1.0,反映了它们的适当利用。一百二十九名患者(37.0%)在研究期间停止治疗。患者的教育水平(OR:0.416,95%CI:0.183-0.943,p=0.036),BMI(OR:2.358,95%CI:1.164-4.777,p=0.017),合并用药的数量(OR:2.457,95%CI:1.202-5.025,p=0.014),和治疗持续时间(OR:9.180,95%CI:4.909-17.165,p<0.001)被鉴定为单克隆抗体停药的预测因子。
■这项研究代表了阿拉伯联合酋长国首次针对治疗模式的全面调查,利用率,以及在当地人群中停止单克隆抗体。规定了单克隆抗体用于管理各种临床状况。该研究报告了大多数单克隆抗体的适当利用,并确定了患者教育水平等因素,BMI,合并用药,和治疗持续时间作为单克隆抗体治疗终止的独立预测因素。
UNASSIGNED: Biological agents have revolutionized care in specialties such as oncology, immunology, infectious diseases, and genetic disorders, offering targeted actions on specific molecules or select immune cells. Monoclonal antibodies, known for their high specificity and precision, represent one of the most significant and rapidly expanding categories of these agents. Understanding the drug
utilization patterns of monoclonal antibodies is crucial to ensure their optimal use, especially given their high cost and potential adverse effects.
UNASSIGNED: This analytical cross-sectional study was conducted in a secondary hospital in the United Arab Emirates. Patients of either gender receiving monoclonal antibodies at the study site were included. Treatment patterns,
utilization, and factors associated with the discontinuation of monoclonal antibodies were assessed.
UNASSIGNED: Hyperlipidemia (136, 39.1%) was the most common indication for monoclonal antibodies, followed by prophylaxis of respiratory syncytial virus infection in congenital heart disease (104, 29.9%) and osteoporosis (42, 12.1%). Evolocumab was the most commonly prescribed monoclonal antibody (135, 38.8%), followed by palivizumab (104, 29.9%), and dupilumab (38, 10.9%). The majority of monoclonal antibodies demonstrated a prescribed daily dose to defined daily dose ratio of 1.0, reflecting their appropriate
utilization. One hundred twenty-nine patients (37.0%) discontinued their treatment during the study. Patient\'s level of education (OR: 0.416, 95% CI: 0.183-0.943, p = 0.036), BMI (OR: 2.358, 95% CI: 1.164-4.777, p = 0.017), number of concomitant medications (OR: 2.457, 95% CI: 1.202-5.025, p = 0.014), and treatment duration (OR: 9.180, 95% CI: 4.909-17.165, p < 0.001) were identified as predictors of discontinuation of monoclonal antibodies.
UNASSIGNED: This study represents the first comprehensive investigation in the United Arab Emirates focused on treatment patterns,
utilization, and discontinuation of monoclonal antibodies among the local population. Monoclonal antibodies were prescribed for the management of a wide range of clinical conditions. The study reports appropriate
utilization of most monoclonal antibodies and identifies factors such as patient education level, BMI, concomitant medications, and treatment duration as independent predictors of monoclonal antibody treatment discontinuation.